Skip to main content

Tykerb Side Effects

Generic name: lapatinib

Medically reviewed by Drugs.com. Last updated on Jun 22, 2023.

Note: This document contains side effect information about lapatinib. Some dosage forms listed on this page may not apply to the brand name Tykerb.

Applies to lapatinib: oral tablet.

Warning

Oral route (Tablet)

Hepatotoxicity, which may be fatal or severe, has been observed in clinical trials and postmarketing experience. Causality of the deaths is uncertain.

Serious side effects of Tykerb

Along with its needed effects, lapatinib (the active ingredient contained in Tykerb) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lapatinib:

More common

Rare

Incidence not known

Other side effects of Tykerb

Some side effects of lapatinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to lapatinib: oral tablet.

Gastrointestinal

Very common (10% or more): Diarrhea (77%), nausea (44%), vomiting (26%), stomatitis (14%), dyspepsia (11%), constipation, abdominal pain[Ref]

Hematologic

Very common (10% or more): Neutropenia (77%), hemoglobin lab abnormality (56%), leukopenia (53%), anemia (23%), neutrophils lab abnormality (22%), platelets lab abnormality (18%), decreased hemoglobin (10%)[Ref]

Dermatologic

Very common (10% or more): Rash (including dermatitis acneiform, 59%), Palmar-plantar erythrodysesthesia (53%), alopecia (13%), dry skin (13%), pruritus (12%), nail disorders (including paronychia, 11%)

Frequency not reported: Serious cutaneous reactions[Ref]

Hepatic

Very common (10% or more): AST lab abnormality (53%), ALT lab abnormality (46%), total bilirubin lab abnormality (45%), increased ALT (11%), hyperbilirubinemia

Common (1% to 10%): Hepatotoxicity[Ref]

Metabolic

Very common (10% or more): Decreased appetite (32%), anorexia (11%)[Ref]

Other

Very common (10% or more): Fatigue (22%), mucosal inflammation (15%), asthenia[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (14%), pain in extremity (12%), back pain (11%), arthralgia[Ref]

Respiratory

Very common (10% or more): Dyspnea (12%), cough (10%), epistaxis

Uncommon (0.1% to 1%): Interstitial lung disease/pneumonitis[Ref]

Psychiatric

Very common (10% or more): Insomnia (10%)[Ref]

Cardiovascular

Very common (10% or more): Hot flush

Common (1% to 10%): Decreased left ventricular ejection fraction[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy

Common (1% to 10%): Headache[Ref]

Hypersensitivity

Rare (less than 0.1%): Hypersensitivity reactions (including anaphylaxis)[Ref]

Frequently asked questions

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals. 2007.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.